v-212
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 29, 2025 (NCT06975319)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Variola virusImmunity, active
Variola virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06975319 | Early Phase 1 (Phase 1) | Jan 29, 2025 | CR2O, Ghent University, Virometix |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CR2O | For profit | 1 | 0 | 1 | 2025 |
| Ghent University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Virometix | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1